Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
41 hedge funds and large institutions have $4.98M invested in Accelerate Diagnostics in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 9 reducing their positions, and 7 closing their positions.
9% more capital invested
Capital invested by funds: $4.55M → $4.98M (+$426K)
11% less funds holding
Funds holding: 46 → 41 (-5)
11% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 9
71% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CIA
Cladis Investment Advisory
Billings,
Montana
|
+$41.5K |
| 2 |
GAM
Griffin Asset Management
New York
|
+$27.6K |
| 3 |
VF
Virtu Financial
New York
|
+$10.9K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$4.33K |
| 5 |
IF
Ironwood Financial
Tucson,
Arizona
|
+$2.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$249K |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$79.7K |
| 3 |
OIM
Oracle Investment Management
Greenwich,
Connecticut
|
-$41.7K |
| 4 |
Northern Trust
Chicago,
Illinois
|
-$29.3K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
-$19.8K |
AXDX Hedge Fund Activity: Q2 2024 in Review
41 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q2 2024, worth a combined $4.98M — up 9.4% from $4.55M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of AXDX and 2 opened new positions — a net loss of 5 holders — while 9 trimmed existing stakes and 8 added.
The largest buyer was Cladis Investment Advisory, opening a new position worth an estimated $41.5K. The largest seller was Armistice Capital, cutting an estimated $249K.
- 41 institutional investors held Accelerate Diagnostics (AXDX) as of Q2 2024, down from 46 in Q1 2024.
- Funds reported $4.98M of Accelerate Diagnostics stock for Q2 2024, up 9.4% quarter-over-quarter.
- 2 funds opened new Accelerate Diagnostics positions in Q2 2024 and 7 closed out, a net change of -5 holders.
- The largest Accelerate Diagnostics buyer in Q2 2024 was Cladis Investment Advisory, an estimated $41.5K added.
- The largest Accelerate Diagnostics seller in Q2 2024 was Armistice Capital, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2024.